Shuttle Pharmaceuticals Holdings (SHPH) Net Income towards Common Stockholders (2021 - 2026)

Shuttle Pharmaceuticals Holdings' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 20.14% year-over-year to -$2.5 million in Q1 2026; TTM through Mar 2026 was -$11.9 million, a 18.87% decrease from a year earlier, with the FY2025 full-year figure at -$19.7 million, down 54.97% from the prior year.
• Net Income towards Common Stockholders rose to -$2.5 million in Q1 2026 per SHPH's latest filing, from -$2.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$623043.0 in Q2 2022 and bottomed at -$4.4 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$1.9 million (2024), against an average of -$2.2 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 807.29% in 2022 and surged 62.7% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$4.4 million in 2022, then jumped by 62.7% to -$1.6 million in 2023, then fell by 4.0% to -$1.7 million in 2024, then sank by 63.39% to -$2.8 million in 2025, then climbed by 9.72% to -$2.5 million in 2026.
• Per Business Quant, the three latest SHPH Net Income towards Common Stockholders figures stand at -$2.5 million (Q1 2026), -$2.8 million (Q4 2025), and -$2.4 million (Q3 2025).